Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › GLORY-2

GLORY-2

Mazdutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Mazdutide
Population
obesity
Official title
A Study of IBI362 9 mg in Chinese Adults With Obesity
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
3
Registry status
unknown · 2023-12 → 2025-06
Participants
462
Duration
60 weeks
Registry
NCT06164873

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
mazdutide 9 mgobesity china60—−18.6 % vs −3.0 %
Δ −15.5 pp
−16.6 % vs −1.5 %
Δ −15.1 pp
—2.9 vs 0.013.0 vs 5.246.9 vs 3.253.1 vs 1.37.2 vs 5.2−9.8 vs −0.2verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (8)
  • mazdutide 9 mg · weight_eff · Results, Coprimary Outcomes, paragraph 1 (eTable 1 in Supple
    the mean percentage change in body weight from baseline to week 60 was -18.55% (95% CI, -19.78% to -17.31%) in the mazdutide group vs -3.02% (95% CI, -4.72% to -1.31%) in the placebo group
  • mazdutide 9 mg · weight_tp · Table 2; Results, Coprimary Outcomes, paragraph 1
    mean percentage change in body weight from baseline to week 60 was -16.65% (95% CI, -18.19% to -15.12%) in the mazdutide group vs -1.50% (95% CI, -3.43% to 0.43%) in the placebo group
  • mazdutide 9 mg · ae_dc · Table 3
    | Any that led to treatment discontinuation | 9 (2.9) | 0 | 2.9 (0.5 to 5.5) |
  • mazdutide 9 mg · disc_any · Results, Participants; Figure 1
    89.6% of participants (267 [87.0%] in the mazdutide group vs 146 [94.8%] in the placebo group) completed the treatment
  • mazdutide 9 mg · nausea · Table 3
    | Nausea | 144 (46.9) | 5 (3.2) | 43.7 (37.1 to 49.7) |
  • mazdutide 9 mg · vomiting · Table 3
    | Vomiting | 163 (53.1) | 2 (1.3) | 51.8 (45.7 to 57.5) |
  • mazdutide 9 mg · sae · Table 3
    | Serious adverse eventsa | 22 (7.2) | 8 (5.2) | 2.0 (-3.3 to 6.3) |
  • mazdutide 9 mg · sbp · Results, Key Secondary Outcomes, paragraph 2; Table 2 (garbl
    systolic blood pressure was -9.80 mm Hg (95% CI, -11.37 to -8.23 mm Hg) in the mazdutide group vs -0.23 mm Hg (95% CI, -2.13 to 1.67 mm Hg) in the placebo group

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: GLORY-2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/glory-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.